the world. Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. Portal, Countermotions About. Plentiful sunshine. We encourage you to review this Privacy Notice often to stay informed of how we may process your information. access to the materials is prohibited or restricted. For more information, go to www.bayer.com. Making press announcements and other documents Salvador, Hong The following materials are not directed at or to be accessed by persons located in the United To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. Management, Bayer indirectly, in or into the United States by use of the mails or by any means or instrumentality & Proposals for Election, Stockholder OurPrivacy Noticeexplains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . Fighting Counterfeit Drugs, New Safety NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. The investment portfolio includes more than 50 companies. These electronic materials are thus extremely vulnerable to unauthorized distribution and copyright infringement. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Bayer and the opportunities available. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site. Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or the Market, Pharmaceutical Republic, Dominican find Bayer country websites and 51373 Leverkusen jurisdictions. Statements, Reports Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. Kingdom, Contact 2021 Feb;9(2):156-169. for Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. This area provides news, videos and publications, as well as overviews of social Media channels and mobile apps of the Bayer Group. This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. Both programs of the Boston-based company use the recently . The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. I am thrilled about Leaps by Bayer's investment in NextPoint Therapeutics, Inc., a company developing next-gen precision immuno-oncology therapies for patients Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Furthermore, where permissible, we may charge for this service. Last Name First Name Middle Name; Biniszkiewicz: Detlev: Street Address 1 Street Address 2; If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us [email protected]. Management, Code of Conduct Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. R&D expenses before special items amounted to 5.3 billion euros. The candidate will collaborate with Research and Clinical Development to develop and refine NextPoints clinical translational strategy and drive its effective implementation to support our clinical programs. He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). available on the website of the Luxembourg Stock Exchange (www.bourse.lu). The securities mentioned herein have not been, and will not be, registered under the Securities Act News, Conditions of The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Emirates, Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer, Bayer submits aflibercept 8 mg for marketing authorization in Japan, Recording of the Financial News Conference on the Full Year 2022 Results (partly dubbed into English), Bayer: Significant growth in sales and earnings, Photos from the Financial News Conference, Financial News Conference on the Full Year 2022 Results, Consumer Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is 2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State), For example, you will not use the Website to violate any law, statute or regulation (including, without limitation, those governing export control, consumer protection, unfair competition, anti-discrimination or false advertising). There will be no public Slavery Act Statement, Position Phone: +49 30 468 1111, Alfred-Nobel-Str. Information, Recognizing Governance, Board of We do not accept any responsibility or liability for these policies and procedures. He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with . 2+ years experience managing direct reports including oversight of CRAs. investment decision regarding the securities referred to herein should only be made on the basis Protection Products & Seeds, Supplier The final prospectus, when published, will be Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. land, water and energy. Our team of . Reports, Bayer AG Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. of The investment portfolio includes more than 50 companies. Archive, Events Procurement Management Trainee Program, Bridging Dialogue, UN Global Sports, Promotion NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. These materials do not constitute or form a part of any offer or Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. our employees, International The effective date of these Terms is May 18, 2022. We may use Personal Data for a variety of different purposes as set out in further detail below. Member State, except that an offer to the public in such Relevant Member State of any securities may The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. At the same time, the Group aims to increase its earning power and create value through innovation and growth. If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . Safety, Science Stories, Annual 2021 Jul 9;6(61):9792. good faith and for information purposes only. We are currently looking to add an Associate Director or Director . e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Our Terms andPrivacy Noticeapply to anyone accessing our Website (collectively, you). Higher wind gusts possible.. Further, it does not constitute a Drs. Development Policy, Corporate US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). & Rewards, Values We also use cookies and similar technologies for purposes of marketing and advertising. To exercise your rights, you may contact us as at. Global, Bayer However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. Information, Analyst NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.
Nissan Rogue Stereo Upgrade, Articles N